Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
Ruggeri, M; Rolli, F R; Kondili, L A; Drago, C; De Solda, F; Nappi, C; Cicchetti, A.
Affiliation
  • Ruggeri M; a Institute of Economic Policy and School of Health Economics and Management , Università Cattolica del Sacro Cuore , Rome , Italy.
  • Rolli FR; b School of Health Economics and Management , Università Cattolica del Sacro Cuore , Rome , Italy.
  • Kondili LA; c Center for Global Health , Istituto Superiore di Sanità , Rome , Italy.
  • Drago C; d Università Niccolò Cusano , Rome , Italy.
  • De Solda F; e Center for Global Health , Bristol-Myers Squibb , Rome , Italy.
  • Nappi C; e Center for Global Health , Bristol-Myers Squibb , Rome , Italy.
  • Cicchetti A; b School of Health Economics and Management , Università Cattolica del Sacro Cuore , Rome , Italy.
Expert Rev Pharmacoecon Outcomes Res ; 19(3): 363-374, 2019 Jun.
Article in En | MEDLINE | ID: mdl-30351994
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antiviral Agents / Hepatitis C, Chronic / Sofosbuvir / Imidazoles Type of study: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antiviral Agents / Hepatitis C, Chronic / Sofosbuvir / Imidazoles Type of study: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Year: 2019 Type: Article